3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Lymphoid
1
Genitourinary
1
CNS
1
Conditions
Sarcoma
2
Wilms Tumor
1
Triple Negative Breast Neoplasms
1
Sarcoma, Synovial
1
Sarcoma, Ewing
1
Rhabdomyosarcoma
1
Rhabdoid Tumor
1
Recurrence
1
Prostatic Neoplasms
1
Ovarian Neoplasms
1
Osteosarcoma
1
Neuroectodermal Tumors, Primitive
1
Neuroblastoma
1
Neoplasms, Neuroepithelial
1
Neoplasms
1
Medulloblastoma
1
Lymphoma, Non-Hodgkin
1
Lymphoma
1
Hodgkin Disease
1
Gliosarcoma
1
Glioma
1
Glioblastoma
1
Esophageal Neoplasms
1
Ependymoma
1
Diffuse Intrinsic Pontine Glioma
1
Desmoplastic Small Round Cell Tumor
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Vincristine
25
Cyclophosphamide
25
Irinotecan
21
Temozolomide
18
Doxorubicin
16
Radiotherapy
15
Filgrastim
15
Ifosfamide
14
Dactinomycin
14
Etoposide
11
Vinorelbine
9
Melphalan
9
Magnetic Resonance Spectroscopy
9
Granulocyte Colony-Stimulating Factor
9
Radiation
8
pegfilgrastim
7
X-Rays
7
Specimen Handling
7
Sirolimus
7
Topotecan
6
Phantoms, Imaging
6
Peripheral Blood Stem Cell Transplantation
6
Gemcitabine
6
cixutumumab
5
Busulfan
5
Biopsy
5
temsirolimus
4
irinotecan sucrosofate
4
fludarabine
4
etoposide phosphate
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Rhabdomyosarcoma
×
CLR1404
×
Sarcoma
×
Clear all
NCT03478462
2026-03-18
CLOVER-2
Cellectar Biosciences, Inc.
Phase 1
Active not recruiting
30 enrolled